bunazosin bunazosin bunazosin (inn) is an α1-adrenergic receptor antagonist. bunazosin was initially developed to treat benign prostatic hyperplasia (bph). it has been approved in japan in a topical form to treat glaucoma. the mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting in lowering the intraocular pressure. it also may act to improve blood flow to the ocular nerve. systemic alpha-1 adrenergic receptor antagonists have been implicated in intraoperative floppy iris syndrome (ifis). bunazosin potentially could have the same effect but there has been no research to substantiate this as a risk for cataract surgery. bunazosinclinical dataahfs/drugs.cominternational drug namesatc codenoneidentifiers iupac name 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl)butan-1-one cas number80755-51-7pubchem cid2472chemspider2378 yunii9uuw4v7g2hchemblchembl188185 ycomptox dashboard (epa)dtxsid7022700 chemical and physical dataformulac19h27n5o3molar mass373.457 g·mol−13d model (jsmol)interactive image smiles cccc(=o)n1cccn(cc1)c2=nc3=cc(=c(c=c3c(=n2)n)oc)oc inchi inchi=1s/c19h27n5o3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12h,4-10h2,1-3h3,(h2,20,21,22) ykey:rhljlalhbzgafm-uhfffaoysa-n y (verify)